KEYNOTE-189: Clinical Implications in Patients with Less Than 1% Tumor PD-L1 Expression

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

KEYNOTE-189: Clinical Implications in Patients with Less Than 1% Tumor PD-L1 Expression

By Beacon Medical Interchange FEATURING Jack West

28 views

November 2, 2018

Dr. Jack West reviews clinical results in patients with advanced non-squamous NSCLC and negative (sub ...
read more ↘ 1%) tumor PD-L1 on the KEYNOTE-189 trial, providing thoughts on the clinical implications of these findings in management of this patient subset.
↖ read less

Comments 0